Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Influenza infections can lead to severe illness and are responsible for up to an estimated 650,000 deaths worldwide annually. The existence of broadly neutralizing antibodies (bnAbs) that target the conserved stem of the viral envelope glycoprotein haemagglutinin (HA) suggests that strain-agnostic therapeutics could be developed. Now, an orally available small molecule that binds to the region of HA that is targeted by bnAbs has been developed. This molecule protected mice from a lethal challenge with influenza virus.